The study, which evaluated the top 20 pharmaceutical companies, identified Amgen, AstraZeneca, and Celgene as the most dedicated to clinical trial data sharing.
Citeline®, an Informa business unit, and the pharmaceutical industry's leading research authority on clinical trials, reported today that clinical trial transparency, also known as responsible data sharing, is in a much healthier state than shown in previous studies, when you refer to the right variety of sources.
Doro Shin, a Citeline analyst, presented the findings of her analysis today at the Pharma CI USA Conference in Parsippany, NJ, an event attended by competitive intelligence experts in the pharmaceutical industry.
"Prior analyses found that 23-57% of completed clinical trials do not report results. However, these analyses only included trials that met specific criteria and none included conference abstracts as a source for results disclosure. As such, I wanted to know what the current status is for results reporting among industry sponsors using broader inclusion criteria and across multiple sources for results," stated Ms. Shin.
Read the complete article: http://bit.ly/1qHBrpM